Richard Law
Stock Analyst at Goldman Sachs
(0.25)
# 3,556
Out of 4,667 analysts
50
Total ratings
11.11%
Success rate
-21.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Initiates: Neutral | $45 | $26.40 | +70.45% | 1 | Sep 30, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $25 → $31 | $19.79 | +56.64% | 2 | Sep 12, 2024 | |
| MLYS Mineralys Therapeutics | Initiates: Buy | $30 | $12.60 | +138.10% | 5 | Apr 2, 2024 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $24 | $8.28 | +189.86% | 4 | Apr 2, 2024 | |
| RCKT Rocket Pharmaceuticals | Initiates: Neutral | $39 | $12.93 | +201.62% | 1 | Apr 2, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Neutral | $62 | $49.82 | +24.45% | 1 | Apr 2, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Neutral | $11 | $8.36 | +31.58% | 4 | Aug 11, 2023 | |
| VERV Verve Therapeutics | Reiterates: Neutral | $31 | $4.50 | +589.66% | 2 | Aug 11, 2023 | |
| BEAM Beam Therapeutics | Maintains: Neutral | $46 → $47 | $24.49 | +91.92% | 3 | Aug 9, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $62 → $63 | $47.26 | +33.31% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $44.05 | -16.00% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $13.12 | +479.27% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.41 | +480.91% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $23.05 | +164.64% | 4 | May 8, 2023 |
Celldex Therapeutics
Sep 30, 2024
Initiates: Neutral
Price Target: $45
Current: $26.40
Upside: +70.45%
Viridian Therapeutics
Sep 12, 2024
Maintains: Buy
Price Target: $25 → $31
Current: $19.79
Upside: +56.64%
Mineralys Therapeutics
Apr 2, 2024
Initiates: Buy
Price Target: $30
Current: $12.60
Upside: +138.10%
Olema Pharmaceuticals
Apr 2, 2024
Initiates: Buy
Price Target: $24
Current: $8.28
Upside: +189.86%
Rocket Pharmaceuticals
Apr 2, 2024
Initiates: Neutral
Price Target: $39
Current: $12.93
Upside: +201.62%
MoonLake Immunotherapeutics
Apr 2, 2024
Initiates: Neutral
Price Target: $62
Current: $49.82
Upside: +24.45%
Monte Rosa Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $8.36
Upside: +31.58%
Verve Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $31
Current: $4.50
Upside: +589.66%
Beam Therapeutics
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $24.49
Upside: +91.92%
CRISPR Therapeutics AG
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $47.26
Upside: +33.31%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $44.05
Upside: -16.00%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $13.12
Upside: +479.27%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.41
Upside: +480.91%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $23.05
Upside: +164.64%